The role of 5-α-reductase inhibition as monotherapy in view of the MTOPS data
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Medical treatment for the symptoms of benign prostatic hyperplasia (BPH) consists of α blockers and 5-α -reductase inhibitors. Data suggest that 5-α -reductase inhibitors can prevent progression of BPH and reduce the risk of BPH-related surgery, especially in men with large-volume prostates. Results from the largest randomized, prospective, placebo-controlled trial, the Medical Therapy of Prostatic Symptoms trial, have been presented. These results support the notion of using 5-α-reductase inhibitors for the prevention of BPH progression and BPH-related surgery. Furthermore, long-term 5-α -reductase inhibitor monotherapy, although slow in onset, is a viable therapy for symptom relief in men with mild to moderate symptoms.
- Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 1984, 132:474–479.
- McConnell JD: Prostatic growth: new insights into hormonal regulation. Br J Urol 1995, 76(suppl 1):5–10.
- Imperato-McGinley J, Guerrero L, Gautieer T, Peterson RE: Steroid 5-alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974, 186:1213–1215. CrossRef
- McConnell JD, Barry MJ, Bruskewitz RC, et al.: Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guidelines. No. 8., AHCPR Publication No 94-0582. Rockville, MD: Agency for Health Care Policy and Research. Public Health Service, US Department of Health and Human Services, 1994.
- Rhodes T, Girman CJ, Jacobsen SJ, et al.: Longitudinal prostate growth rates during 5 years in randomly selected men 40–79 years old. J Urol 1999, 161:1174–1179. CrossRef
- Girman CJ, Jacobsen SJ, Guess HA, et al.: Natural history of prostatism: relationship among symptoms, prostate volume, and peak urinary flow rate. J Urol 1995, 153:1510–1515. CrossRef
- Roehrborn CG, Boyle P, Bergner D, et al.: Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a 4-year, randomized trial comparing finasteride versus placebo. Urology 1999, 54:662–669. The first long-term study of 5-α -reductase, finasteride, in the treatment of BPH documenting safety and efficacy in a multicenter, randomized, placebo-controlled trial. CrossRef
- Hoffman RM, MacDonald R, Slaton JW, Wilt TJ: Laser prostatectomy versus transurethral resection for treating benign prostatic obstruction: a systematic review. J Urol 2003, 169:210–215. CrossRef
- Tunuguntla HS, Evans CP: Minimally invasive therapies for benign prostatic hyperplasia. World J Urol 2002, 20:197–206.
- Gup DI, Shapiro E, Bauman M, Lepor H: Contractile properties of human prostate adenomas ant the development of infravesical obstruction. Prostate 1989, 15:105–114. CrossRef
- Lepor H, Auerbach S, Puras-Baez A, et al.: A randomized, placebo-controlled, multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992, 148:1467–1474.
- Fawzy A, Braun K, Lewis GP, et al.: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995, 154:105–109. CrossRef
- Gillenwater JY, Conn RL, Chrysant SG, et al.: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild-to-moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995, 154:110–115. CrossRef
- Lepor H: Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998, 51:892–900. CrossRef
- AUA Practice Guideline Committee: AUA Guidelines on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003, 170:530–547. The recent publication of practice guidelines on the management of BPH by an AUA guideline committee. This publication is an update of the AHCPR guideline published in 1994. CrossRef
- Gromley GJ, Stoner E, Bruskewitz RC, et al.: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992, 327:1185–1191. CrossRef
- Beisland HO, Binkowitz B, Brekkan E, et al.: Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. Eur Urol 1992, 22:271–277.
- Lepor H, Williford WO, Barry MJ, et al.: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996, 335:533–539. CrossRef
- McConnell JD, Bruskewitz R, Walsh P, et al.: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998, 338:557–563. CrossRef
- Bruskewitz R, Girman CJ, Fowler J, et al.: Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. Urology 1999, 54:670–678. CrossRef
- Kaplan SA, Holtgrewe HL, Bruskewitz R, et al.: Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology 2001, 57:1073–1077. CrossRef
- Matsumoto AM, Tenover L, McClung M, et al.: The long-term effect of specific type II 5-alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol 2002, 167:2105–2108. CrossRef
- Schafer W, Tammela TL, Barrett DM, et al.: Continued improvement in pressure-flow parameters in men receiving finasteride for 2 years. Urology 1999, 54:278–283. CrossRef
- Bautista OM, Kusek JW, Nyberg LM, et al.: Study design of the Medical Therapy of Prostate Symptoms (MTOPS) trial. Control Clin Trials 2003, 24:224–243. CrossRef
- McConnell J: The impact of medical therapy on clinical progression of BPH: results of MTOPS trial [Abstract]. J Urol 2002, 1042:265. The first public presentation of the MTOPS data at the national AUA meeting.
- Roehrborn CG, Boyle P, Nickel JC, et al.: Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002, 60:434–441. This study confirmed the safety and efficacy of 5-α-reductase therapy with a dual type-1 and type-2 5-α -reductase inhibitor therapy. CrossRef
- Lowe FC, McConnell JD, Hudson PB, et al.: Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 2003, 61:791–796. CrossRef
- Lam JS, Romas NA, Lowe FC: Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Urology 2003, 61:354–358. CrossRef
- Baldwin KC, Ginsberg PC, Roehrborn CG, Harkaway RC: Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001, 58:203–208. CrossRef
- Barkin J, Guimaraes M, Jacobi G, et al.: Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5-alpha-reductase inhibitor dutasteride. Eur Urol 2003, 44:461–466. CrossRef
- Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215–224. CrossRef
- Scardino PT: The prevention of prostate cancer: the dilemma continues. N Engl J Med 2003, 349:297–299. CrossRef
- Kearney MC, Bingham JB, Bergland R, et al.: Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia. J Urol 2002, 167:2489–2491. CrossRef
- Pareek G, Shevchuk M, Armenakas NA, et al.: The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 2003, 169:20–23. CrossRef
- Hagerty JA, Ginsberg PC, Harmon JD, Harkaway RC: Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology 2000, 55:684–689. CrossRef
- Donahue JF, Sharma H, Abraham R: Transurethral prostate resection and bleeding: a randomized, placebo-controlled trial of the role of finasteride for decreasing operative blood loss. J Urol 2002, 168:2024–2026. CrossRef
- The role of 5-α-reductase inhibition as monotherapy in view of the MTOPS data
Current Prostate Reports
Volume 2, Issue 1 , pp 30-35
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links